Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in the same period last year, marking the highest quarterly revenues to date [4][23] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [5] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [24] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching approximately 8,500 average patients on WAKIX [4][10] - The company is guiding WAKIX net revenue to blockbuster status of $1 billion-$1.04 billion for 2026, reflecting strong expectations for continued growth [5][25] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for WAKIX [5] - The recent FDA approval of WAKIX for the treatment of cataplexy in pediatric patients aged 6 years and older is expected to enhance market penetration [12] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the next-generation pitolisant formulations, including pitolisant GR and pitolisant HD, targeting unique indications in orphan rare diseases and broader CNS indications [7][9] - The company is advancing a robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications, aiming for multiple catalysts over the next few years [8][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, supported by strong commercial execution and a clear path for growth [9][28] - The company remains committed to defending its intellectual property and is optimistic about the potential for pediatric exclusivity for WAKIX [7][28] Other Important Information - Harmony ended Q4 2025 with approximately $882.5 million in cash equivalents and investments, providing financial flexibility for growth initiatives [23] - The company is expanding its field-based teams by nearly 20% to enhance market presence and support continued growth [11] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the baseline anti-seizure med use for EPX-100 in Dravet syndrome? - Management noted that patients had treatment-resistant seizures and comparable baseline seizure rates to other studies, with a median reduction in seizures of approximately 50% [30][32] Question: What is the PK, PD, and safety bar for the orexin 2 receptor agonist in phase 1 studies? - Management indicated that they expect to confirm the expected profile of once-daily dosing and are making progress towards advancing the program [38][39] Question: Can you clarify the increase in SG&A expenses in Q4? - The increase was primarily driven by R&D investments for phase 3 studies and litigation expenses related to ANDA settlements [60][62] Question: What is the timeline for decisions expected in ongoing litigation? - Management stated that the timeline for a ruling is uncertain, but they are confident in their position following recent settlements with generic filers [74][76]

Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in Q4 2024, marking the highest quarterly revenues to date [3][22] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [4] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [23] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching about 8,500 average patients on the drug [3][4] - The company anticipates WAKIX net revenue to reach blockbuster status of $1 billion-$1.04 billion in 2026, driven by strong demand and market opportunity [4][10] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for continued growth of WAKIX [4] - The recent FDA approval of WAKIX for treating cataplexy in pediatric patients aged 6 years and older is expected to enhance market penetration [10][95] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the upcoming NDA submission for Pitolisant GR in Q2 2026 and a target PDUFA date in Q1 2027 [5][26] - The company is also exploring broader CNS indications with a new formulation of pitolisant, supported by newly licensed IP with patent protection until 2042 [6][17] - A robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications is in place, setting the stage for multiple catalysts [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, citing strong execution and market demand [4][26] - The company is well-positioned with a strong balance sheet, approximately $882.5 million in cash equivalents, to fund growth and pipeline advancements [22][24] Other Important Information - The company has settled with six of the seven ANDA filers regarding WAKIX, with generic entry not expected before March 2030 if pediatric exclusivity is granted [5][50] - Significant increases in R&D investments are anticipated as the company advances its pipeline, with five registrational studies ongoing and a sixth planned [25][63] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the emerging benefit-risk profile for EPX-100? - Management noted that patients in the Dravet syndrome study had treatment-resistant seizures, with a median reduction in seizures of approximately 50% and a favorable safety profile compared to other medications [30][32] Question: What is the PK, PD, and safety bar for the orexin 2 receptor agonist? - Management indicated that they expect to see clinical PK data by mid-2026 and are making progress towards advancing the program to the next stage of development [39][41] Question: Can you clarify the increase in SG&A expenses in Q4? - The increase was primarily driven by R&D investments for Phase 3 studies and litigation expenses related to ANDA settlements [62][63] Question: What is the timeline for decisions regarding ongoing litigation? - Management stated that the timeline for a ruling is uncertain, but they remain confident in their IP strength and the settlements achieved with generic filers [78][79]

Harmony Biosciences FY Conference Summary Company Overview - **Company**: Harmony Biosciences (NasdaqGM:HRMY) - **Industry**: Biotechnology, specifically focusing on treatments for narcolepsy and epilepsy Key Points and Arguments Business Performance and Growth - Harmony Biosciences has established a strong commercial foundation, particularly with its product Wakix, which targets narcolepsy and is projected to be a $1 billion-plus opportunity in this market [2][3] - The company is profitable and self-funding its activities, allowing for continued growth in both its pipeline and commercial portfolio [3][4] Wakix Franchise - Wakix has shown consistent performance with a steady increase in patient numbers, reporting an increase of 400 patients in Q2 and 500 patients in Q3, leading to an upward revision of revenue guidance from $820-$860 million to $845-$865 million for the year [6][7] - The product is differentiated as the only non-scheduled treatment for narcolepsy, which is well tolerated and has a unique mechanism of action [8][10] - The company plans to maintain its competitive edge through life cycle management strategies, including new formulations such as gastro-resistant (GR) and high-dose (HD) versions of pitolisant [10][11] Pipeline Developments - Harmony is advancing its pipeline with new formulations and additional assets, including orexin-2 agonists currently in phase one clinical trials and EPX-100 for epilepsy in phase three trials [3][4] - Upcoming data presentations at the American Epilepsy Society meeting are expected to provide new efficacy data for EPX-100 [3] Market Dynamics and Competitive Position - The narcolepsy market is characterized by a high discontinuation rate of 30%-50% for medications, but once patients are stabilized on Wakix, they tend to remain on therapy [17] - The company emphasizes that Wakix's unique profile will remain competitive despite the introduction of generics in the market [15][16] Future Strategies - The GR formulation aims to provide a faster therapeutic effect without the need for titration, while the HD formulation targets improved efficacy and new indications for fatigue in narcolepsy patients [11][19] - Harmony is also exploring business development opportunities to expand its commercial portfolio and pipeline further [34] Challenges and Considerations - The company is currently assessing the future of its Cannabidiol Gel (ZYN002) program following disappointing phase three results, with plans to provide updates after a thorough data review [31][32] - The transition from a single product focus to a multi-franchise business model requires careful organizational growth to ensure all programs receive adequate attention [33] Additional Important Insights - The company has a robust commercial engine and is looking to leverage its balance sheet to drive further value through business development [34] - The ongoing clinical trials and product developments are expected to enhance Harmony's position in the biotechnology sector, particularly in the treatment of sleep disorders and epilepsy [3][4]